Novo Nordisk Slashes Wegovy Prices in India, Emcure to Lead Distribution Under New Brand

Novo Nordisk Expands India Reach With Wegovy Price Cut and Emcure Tie-Up  
In a strategic push to make obesity treatment more accessible, Danish drugmaker Novo Nordisk has cut the price of its blockbuster weight-loss drug Wegovy (semaglutide 2.4 mg) in India. The company has partnered with Pune-based Emcure Pharmaceuticals to distribute the drug under a new brand name, Poviztra. According to documents reviewed by Reuters and filings referenced on the NSE, the price reduction is part of a broader initiative to penetrate deeper into India’s obesity market, which affects over 600 million people.

Emcure becomes the first Indian pharma company with exclusive rights to market Poviztra. The drug, launched just five months ago, will now be available through wider pharmacy networks, especially in regions not previously served by Novo Nordisk India. The collaboration combines Novo’s innovation in GLP-1 therapies with Emcure’s distribution strength.

Major takeaways  

• Novo Nordisk cuts Wegovy prices in India to improve affordability  
• Drug rebranded as Poviztra and distributed by Emcure Pharmaceuticals  
• Emcure gains exclusive rights for semaglutide 2.4 mg in India  
• India’s obesity burden exceeds 600 million people  
• NSE circular confirms strategic partnership with no material financial impact  

Sources: The Hindu Business Line, Financial Express, Livemint, Fierce Pharma, Economic Times, Hindustan Times, Reuters